Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Quaternary Ammonium Palmitoyl Glycol Chitosan
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Virpax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AnQlar (quaternary ammonium palmitoyl glycol chitosan) is a nanoparticle intended to prevent the spread of negatively charged viruse such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at no...
Product Name : AnQlar
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Quaternary Ammonium Palmitoyl Glycol Chitosan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Virpax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of dementia related to AD, bipolar disorder, MDD, and PTSD.
Product Name : AL001
Product Type : Antibody
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : ADP101
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Alladapt Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Alladapt in their important goal of developing a single therapeutic ADP101, to address a wide range of mono- and multi-food allergies, and looking forward to fulfilling their Phase III and commercial requirements.
Product Name : ADP101
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2022
Lead Product(s) : ADP101
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Alladapt Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Virpax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epoladerm (diclofenac epolamine) first-in-human study will be conducted in Q2 2022 and is supplied in a pre-filled device for administration as a topical spray film for treatment of chronic pain associated with osteoarthritis of the knee.
Product Name : Epoladerm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Virpax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegtarazimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects.
Product Name : RLS-0071
Product Type : Peptide
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Pegtarazimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Altasciences Performs Phase I Studies for FDA Approval of Vibegron
Details : Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2021
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
